Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo- controlled multicenter study

Gynecologic Oncology

Volumn 65, Issue 3, 1997, Pages 461-466

  Kurz, Ch ^a   Marth, Ch ^b   Windbichler, G ^b   Lahousen, M ^c   Medl, M ^d   Vavra, N ^a   Sevelda, P ^d  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FERRITIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; GYNECOLOGIC CANCER; HEMOGLOBIN DETERMINATION; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031172237     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4675     Document Type: Article

References (18)

1. 1. Abels RI: Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19(3 Suppl 8):29-35, 1992
2. 2. Abels RI: Recombinant human erythropoietin in the treatment of anemia of cancer. Acta Haematol 87(Suppl 1):4-11, 1992
3. 3. Hasegawa I, Tanaka K: Serum erythropoietin levels in gynecologic cancer patients during cisplatin combination chemotherapy. Gynecol Oncol 46:65-68, 1992
4. 4. Henry DH, Abels RI: Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21(2 Suppl 3):21-28, 1994
5. 5. Wood PA, Hrushesky WJ: Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 95(4):1650-1659, 1995
6. 6. Miller CM, Jones RJ, Piantadosi S, Abeloff MD, Spirak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689-1691, 1990
7. 7. Falkson CI, Keren-Rosenberg S, Uys A, Falkson G, Stevens K, Vermaak WJ: Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology 51(6):497-501, 1994
8. 8. Cascinu S, Fedeli A, Del-Ferro E, Luzi Fedeli S, Catalano G: Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12(5): 1058-1062, 1994
9. 9. Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, Umek H: Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol 4:161-167, 1993
10. 10. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Salmonigg H, Schuster J: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84(4):1056-1063, 1994
11. 11. Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr, Barakat R, Curtin J, Almadrones L, Hoskins W: The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 49:172-176, 1993
12. 12. Means RT Jr, Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80(7):1639-1647, 1992
13. 13. Skillings JR, Sridhar FG, Wong C, Paddock L: The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol 16(1):22-25, 1993
14. 14. Beguin Y, Loo M, R'Zilk S, Sautois B, Lejeune F, Rorive G, Fillet G: Early prediction of response in recombinant human erythropoietin in patients with the anaemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82:2110, 1993
15. 15. Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73(10):2535-2542, 1994
16. 16. Schipper H, Clinch J, McMurray A: Measuring the quality of life of cancer patients: the functional living index - cancer: development and validation. J Clin Oncol 2:472-478, 1984
17. 17. Gill TM, Feinstein AR: A critical appraisal of the quality of quality-of-life measurements. JAMA 272:619-626, 1994
18. 18. Priestman TJ, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 899-901, 1976